Fundraising Fox

ReAlta Life Sciences

Norfolk, US · Founded 2017 · Delaware corporation · 1 known investors

ReAlta Life Sciences develops pegtarazimod, a drug candidate that modulates upstream inflammatory pathways (neutrophils and complement) and is in Phase 2 clinical trials for neonatal Hypoxic Ischemic Encephalopathy (HIE). The compound is positioned as a platform asset with potential applications across multiple inflammatory diseases.

BiotechHealthtech

Founders & leadership

ReAlta Life Sciences was founded in 2017 by Neel Krishna and Kenji Cunnion.

NKNeel Krishna
Neel KrishnainCo-founder
KC
Kenji CunnioninCo-founder
JR
John RickmaninExecutive
PM
Paolo MartiniinExecutive
DM
David MarekinExecutive
UT
Ulrich ThienelNamed on SEC filing
JN
Jerry NadlerNamed on SEC filing
JH
John HardingNamed on SEC filing

Board

AM
Andrew MillerBoard director
MA
Mert AktarBoard director
TK
Thomas Kerry McCarterManaging Director
LW
Lewis WilliamsBoard director

Investors · 1

Also in the syndicate · 1

Massinvestor, Inc.

Funding

SEC filings, press & company announcements

$134.3M disclosed across 6 of 8 rounds · 2018–2026

  • $40MraisedApr 2026 · 4 sources

    Massinvestor, Inc.

    Source ↗
▶$29.9MraisedMay 2025 · 149 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • John RickmanExecutive Officer
  • Andrew MillerDirector
  • Neel KrishnaExecutive Officer
  • Lewis WilliamsDirector
  • Frank GadamsDirector
  • Kenji CunnionExecutive Officer
  • Paolo MartiniExecutive Officer
  • Mert AktarDirector
  • Edward Heidt, Jr.Director
  • Laurie GlimcherDirector
  • Christi ShawDirector
  • David MarekExecutive Officer, Director
  • Emma ReeveDirector
Offering amount
$30M
Amount sold
$29.9M
First sale
Nov 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$25MraisedMay 2025 · 109 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Laurie GlimcherDirector
  • David MarekExecutive Officer, Director
  • Edward Heidt, Jr.Director
  • Lewis WilliamsDirector
  • Andrew MillerDirector
  • Kenji CunnionExecutive Officer
  • John RickmanExecutive Officer
  • Frank GadamsDirector
  • Paolo MartiniExecutive Officer
  • Emma ReeveDirector
  • Mert AktarDirector
  • Christi ShawDirector
  • Neel KrishnaExecutive Officer
Offering amount
$25M
Amount sold
$25M
First sale
Dec 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$12MraisedMay 2025 · 85 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Andrew MillerDirector
  • Paolo MartiniExecutive Officer
  • Frank GadamsDirector
  • Laurie GlimcherDirector
  • John RickmanExecutive Officer
  • David MarekExecutive Officer, Director
  • Mert AktarDirector
  • Neel KrishnaExecutive Officer
  • Lewis WilliamsDirector
  • Kenji CunnionExecutive Officer
  • Christi ShawDirector
  • Emma ReeveDirector
  • Edward Heidt, Jr.Director
Offering amount
$12M
Amount sold
$12M
First sale
Feb 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$22.5MraisedSep 2023 · 92 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Edward Heidt, Jr.Director
  • Deborah GeraghtyDirector
  • Jonathan ZalevskyDirector
  • Christine NeikirkDirector
  • John RickmanExecutive Officer
  • Neel KrishnaExecutive Officer
  • Azmi NabulsiDirector
  • Kathryn AbshireExecutive Officer
  • Barry StrasnickDirector
  • Ulrich ThienelExecutive Officer, Director
  • Frank GadamsDirector
  • Kenji CunnionExecutive Officer, Director
Offering amount
$22.5M
Amount sold
$22.5M
First sale
Dec 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2MofferedFeb 2020 · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Edward Heidt, Jr.Executive Officer, Director
  • Thomas Kerry McCarterExecutive Officer
  • Jonathan ZalevskyDirector
  • Azmi NabulsiDirector
  • Deborah GeraghtyDirector
  • Frank GadamsDirector
  • Barry StrasnickDirector
  • Christine NeikirkDirector
  • John RickmanExecutive Officer
  • Neel KrishnaExecutive Officer
  • Ulrich ThienelExecutive Officer, Director
  • Kenji CunnionExecutive Officer, Director
Offering amount
$2M
Minimum investment
$75K
Incorporated
Corporation, Delaware, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$12MofferedOct 2019 · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Ulrich ThienelExecutive Officer, Director
  • Kenji CunnionExecutive Officer, Director
  • Neel KrishnaExecutive Officer
  • John HardingExecutive Officer, Director
  • Barry StrasnickDirector
  • Edward Heidt, Jr.Director
  • Frank GadamsDirector
  • Thomas Kerry McCarterExecutive Officer
  • John RickmanExecutive Officer
Offering amount
$12M
Proceeds to insiders
$619K
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$4.8MraisedSep 2018 · 1 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Edward Heidt, Jr.Director
  • Ulrich ThienelDirector
  • Jerry NadlerDirector
  • Neel KrishnaExecutive Officer
  • Thomas Kerry McCarterExecutive Officer
  • John HardingDirector
  • Kenji CunnionExecutive Officer, Director
Offering amount
$12M
Amount sold
$4.8M
Proceeds to insiders
$14K
First sale
Sep 2018
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Non-dilutive funding · 1 SBIR/STTR award

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase II2019$1.5M

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

In the news

ReAlta lands $40m to back trial of first-in-class infant brain injury therapy - Clinical Trials Arenaclinicaltrialsarena.com · Apr 2026ReAlta Life Sciences Closes $40M Funding for Inflammatory Disease Treatmentsinforcapital.com · Apr 2026ReAlta Life Sciences Closes Oversubscribed $40 Million Financing Round to Advance Pegtarazimod Phase 2 Program in Hypoxic Ischemic Encephalopathy (HIE)businesswire.com · Apr 2026ReAlta Life Sciences Raises $40M in Fundingfinsmes.com · Apr 2026ReAlta Life Sciences Raises $20M in Series A3 Financing - FinSMEsfinsmes.com · Apr 2021ReAlta Life Sciences 4/8/2026 Capital Raise - Gaebler.com Venture Capital Databasegaebler.com

Frequently asked questions

What does ReAlta Life Sciences do?
ReAlta Life Sciences develops pegtarazimod, a drug candidate that modulates upstream inflammatory pathways (neutrophils and complement) and is in Phase 2 clinical trials for neonatal Hypoxic Ischemic Encephalopathy (HIE). The compound is positioned as a platform asset with potential applications across multiple inflammatory diseases.
Who founded ReAlta Life Sciences?
ReAlta Life Sciences was founded by Neel Krishna, Kenji Cunnion in 2017.
How much funding has ReAlta Life Sciences raised?
ReAlta Life Sciences has disclosed $134.3M raised across 6 of its 8 known rounds.
Where is ReAlta Life Sciences headquartered?
ReAlta Life Sciences is headquartered in Norfolk, US.